Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose

Patent metadata

Field	Value
Publication number	US-11542309-B2
Application number	US-202016929342-A
Country	US
Kind code	B2
Filing date	Jul 15, 2020
Priority date	Jul 31, 2019
Publication date	Jan 3, 2023
Grant date	Jan 3, 2023

Abstract

The present disclosure provides FGF1 mutant proteins, which selectively bind to/activate FGFR1b. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed FGF1 mutants to reduce blood glucose in a mammal and treat a metabolic disorder are provided.

First claim

We claim:

1. A method of reducing blood glucose in a mammal, comprising:
administering to the mammal a therapeutically effective amount of a mutated mature fibroblast growth factor (FGF) 1 protein comprising at least 95% sequence identity to SEQ ID NO: 10, and retaining the N7H, N18D, D32E, Y64C, F85L, E90G, K101R, and N114S amino acid substitutions, thereby reducing the blood glucose.

2. The method of claim 1 , wherein the method reduces fed and fasting blood glucose, improves insulin sensitivity and glucose tolerance, reduces systemic chronic inflammation, ameliorates hepatic steatosis in a mammal, or combinations thereof.

3. The method of claim 1 , wherein the therapeutically effective amount of the mutated mature FGF1 protein is at least 0.1 mg/kg.

4. The method of claim 1 , wherein the administering is subcutaneous, intraperitoneal, intramuscular, intravenous or intrathecal.

5. The method of claim 1 , wherein the mammal is a human, cat or dog.

6. The method of claim 1 , wherein the method further comprises administering to the subject a therapeutically effective amount of an additional therapeutic compound.

7. The method of claim 6 , wherein the additional therapeutic compound is insulin, an alpha-glucosidase inhibitor, amylin agonist, dipeptidyl-peptidase 4 (DPP-4) inhibitor, meglitinide, sulfonylurea, or a peroxisome proliferator-activated receptor (PPAR)-gamma agonist.

8. The method of claim 7 , wherein the PPAR-gamma agonist is a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar.

9. The method of claim 8 , wherein the TZD is pioglitazone, rosiglitazone, rivoglitazone, or troglitazone.

10. The method of claim 7 , wherein the mutated mature FGF1 protein has
decreased mitogenicity compared to a native mature FGF1 protein (SEQ ID NO: 2, 4, 5, 6, 7, 8 or 9);
increased blood glucose lowering ability compared to a native mature FGF1 protein (SEQ ID NO: 2, 4, 5, 6, 7, 8 or 9); or
both.

11. The method of claim 1 , wherein the mutated mature FGF1 protein is 90 to 140 amino acids in length.

12. The method of claim 1 , wherein the mutated mature FGF1 protein comprises a deletion of 6, 7, 8, 9, 10, 11, or 12 contiguous N-terminal amino acids from a native FGF1 protein.

13. The method of claim 12 , wherein the deleted contiguous N-terminal amino acids are replaced with the amino acid sequence comprising or consisting of MRDSSPL (SEQ ID NO: 14), SYNHLQGDVR (SEQ ID NO: 15), SYNHLQGDVRV (SEQ ID NO: 16), or SYDYMEGGDIRV (SEQ ID NO: 17).

14. The method of claim 1 , wherein the mutated mature FGF1 protein further comprises at least one additional amino acid substitution selected from N7H, K10E, L13P, G19R, L44P, S76P, I98T, K113Q, and K118E.

15. The method of claim 1 , wherein the mutated mature FGF1 protein comprises at least 96% sequence identity to SEQ ID NO: 10, and retains the N7H, N18D, D32E, Y64C, F85L, E90G, K101R, and N114S amino acid substitutions.

16. The method of claim 1 , wherein the mutated mature FGF1 protein comprises at least 97% sequence identity to SEQ ID NO: 10, and retains the N7H, N18D, D32E, Y64C, F85L, E90G, K101R, and N114S amino acid substitutions.

17. The method of claim 1 , wherein the mutated mature FGF1 protein comprises at least 98% sequence identity to SEQ ID NO: 10, and retains the N7H, N18D, D32E, Y64C, F85L, E90G, K101R, and N114S amino acid substitutions.

18. The method of claim 1 , wherein the mutated mature FGF1 protein comprises at least 99% sequence identity to SEQ ID NO: 10, and retains the N7H, N18D, D32E, Y64C, F85L, E90G, K101R, and N114S amino acid substitutions.

19. The method of claim 1 , wherein the mutated mature FGF1 protein comprises SEQ ID NO: 10.

20. The method of claim 1 , wherein the mammal is a human.

Assignees

• Salk Inst For Biological Studi

Inventors

• Evans Ronald M
• Downes Michael
• Atkins Annette
• Liu Sihao
• Yu Ruth T

Classifications

• A61P3/10 Primary

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K14/50 Primary

  Fibroblast growth factor [FGF] · CPC title